http://www.fiercebiotech.com/biotech/merck-talks-i-o-combo-strate...

http://www.fiercebiotech.com/biotec...gy-as-keytruda-nabs-first-line-nsclc-approval

Merck made a point to highlight a couple of novel immunotherapies, particularly Amgen’s ($AMGN) T-Vec cancer vaccine and Incyte’s ($INCY) IDO inhibitor.

“With immune active agents like T-Vec, there's impressive evidence of activity. There's evidence of activity with other immunologic agents, but there's also as we've talked about very impressive combination activity with chemotherapy,”

However, not to get VLA investors too wound up, the article also points out...

The pharma is leaving no stone unturned in its Keytruda combo efforts; it has more than 200 ongoing combination studies in more than 30 different tumor types. The PD-1 inhibitor is in more than 30 registration studies in 22 different malignancies with in excess of 360 clinical studies in total as a monotherapy and combo.